Biotechnology Companies Making Major Announcements - Seite 2

Heat Biologics, Inc. (NASDAQ: HTBX)

Market Cap: $23.6M, current share price: $4.17 

HTBX is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. HTBX has almost doubled in share price following the announcement of positive interim Phase 2 results for HS-110 in non-small cell lung cancer (NSCLC) and guidance on upcoming clinical milestones for HS-110, its ComPACT™ platform and PTX-35, a co-stimulator antibody being developed by its subsidiary, Pelican Therapeutics. An anticipated $6.9M grant from the Cancer Prevention Research Institute of Texas and multiple upcoming clinical milestones means investors should keep a close eye on HTBX.

Neovasc, Inc. (NASDAQ: NVCN)

Market Cap: $67.2M, current share price: $0.04  

NVCN is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies. Its products include the Reducer, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. The company recently provided a general corporate update, concurrent with filing its Annual Report on Form 20-F, to highlight the Company's progress over the last month and to confirm the date of the earnings call where these matters will be discussed further. The drastic drop in NCVN's share price has resulted in its future-priced warrants and notes being even more dilutive than previously estimated. The Company will also be seeking shareholder approval at the next Annual and Special General Meeting, scheduled for June 4, 2018, to carry out a share consolidation at an appropriate time.